Arkansas Medicaid GLP-1 Coverage 2026: Three-Program Bifurcation + 3 Separate DUR-Board PA Documents + ACT 628 Legislative Ratification

TL;DR

Arkansas Medicaid does NOT cover GLP-1 receptor agonists for adult chronic weight management. The AR DUR Board recurring operational sentence states verbatim: “Arkansas Medicaid does not currently cover medications solely for the use of weight loss.” That exclusion is anchored at four independent authorities and, since January 1, 2026, additionally ratified by statute.

Understanding Arkansas requires tracking three structurally distinct sub-programs with different pharmacy benefit architectures:

• FFS + ARKids B + ARKids A (aged/blind/disabled, dual-eligibles, categorical eligibles) — pharmacy benefit through the state PDL and DUR Board PA criteria, PBM is Prime Therapeutics State Government Solutions (Help Desk 1-800-424-7895, ePA via CoverMyMeds effective Aug 1, 2025)
• PASSE (Provider-led Arkansas Shared Savings Entities — BH/SUD/DD population, ~50,000 lives: CareSource PASSE, Empower, Summit Community Care) — follows the AR Medicaid state PDL per CareSource PASSE’s verbatim statement; same coverage outcomes as FFS
• ARHOME (Section 1115 demonstration expansion for new adults 19–64 at 0–138% FPL, ~240,000–280,000 lives) — pharmacy benefits administered by QHP carriers (Health Advantage/BCBS, Ambetter/Centene) via a “Metallic Drug List” that is outside the state PDL and DUR Board PA criteria entirely

For FFS and PASSE members, three FDA-label-restricted carve-outs are available via three separate standalone DUR-Board-approved PA Criteria documents (not a unified form like Iowa):

No coverage exists for Wegovy or Zepbound for chronic weight management, Saxenda (liraglutide for obesity — explicitly listed as “Non-covered benefit” per Arkansas Total Care’s May 16, 2023 provider news), or any other anti-obesity drug at any BMI threshold.

The 2025 AR Legislature’s action was unambiguous: HB 1332 (GLP-1 mandate) died in Senate committee on May 5, 2025; HB 1424 / ACT 628 enacted a bariatric surgery mandate with explicit statutory exclusion at § 20-77-154(c): “This section does not require the Arkansas Medicaid Program to provide coverage for injectable drugs to lower glucose levels or any other drugs prescribed for weight loss.” This is the cleanest legislative ratification of a GLP-1 exclusion in the 34-state series.

ARHOME exception: if you are enrolled in an ARHOME QHP, your Wegovy/Zepbound coverage is determined by your QHP carrier’s Metallic Drug List — not by the state PDL or DUR Board. Contact your QHP member services line, not Prime Therapeutics.

The Three-Way Program Bifurcation: FFS, PASSE, and ARHOME

Arkansas Medicaid covers approximately 820,000–900,000 Arkansans across three structurally distinct delivery systems. Each has a different pharmacy benefit architecture — a bifurcation that the August 14, 2024 DUR Board memorandum (signed by Cynthia Neuhofel, Pharm.D., DMS Assistant Director/ Pharmacy Director) made explicit in the diabetic-supplies section:

“This program does not apply to members with dual Medicare/Medicaid or those managed in the ARHome program by a QHP.”

Track 1: FFS + ARKids B (State PDL + DUR Board PA)

Fee-for-Service serves aged/blind/disabled (ABD), dual-eligibles, ARKids B, family planning, and other categorical eligibles. Pharmacy benefit flows through the state PDL and DUR Board PA criteria, administered by Prime Therapeutics State Government Solutions as PBM. The DUR Board meets quarterly (January, April, July, October) and recommends PA criteria adopted by DMS. This is the track where all three GLP-1 carve-out PA documents apply.

Track 2: PASSE (BH/SUD/DD Managed Care, ~50,000 Lives)

The Provider-led Arkansas Shared Savings Entity (PASSE) program, launched March 2019, is Arkansas’s targeted full-risk managed care model for beneficiaries with Serious Mental Illness (SMI), Substance Use Disorder (SUD), and developmental disabilities (DD). Current PASSE entities: CareSource PASSE, Empower Healthcare Solutions, and Summit Community Care (Anthem subsidiary).PASSE is NOT general Medicaid managed care — it serves only the ~50,000 SMI/SUD/DD population.

CareSource PASSE states verbatim: “CareSource PASSE follows Arkansas Medicaid’s defined preferences to brand medications on the state’s PDL.” Coverage outcomes for PASSE members are therefore identical to FFS for GLP-1s. Claims processing may route through different PBMs (Express Scripts for CareSource PASSE at 1-800-922-1557); the underlying PA criteria are state-PDL-defined.

Track 3: ARHOME Expansion (~240,000–280,000 Lives)

Arkansas Health and Opportunity for Me (ARHOME) is the Section 1115(a) demonstration-waiver-based expansion for new adults (ages 19–64, 0–138% FPL) launched January 1, 2022 (successor to Arkansas Works / the Private Option). ARHOME’s architecture is structurally unique in the 34-state series: Medicaid funds purchase coverage from private Qualified Health Plans (QHPs) through the Federally Facilitated Marketplace. QHP carriers include Blue Cross Blue Shield (Health Advantage) and Ambetter (Centene).

ARHOME pharmacy benefits are governed by each QHP’s “Metallic Drug List” — not the AR state PDL and not the DUR Board PA criteria. This means an ARHOME beneficiary’s Wegovy or Zepbound coverage is independently determined by their QHP carrier. Whether an ARHOME QHP covers Wegovy for chronic weight management depends on that QHP’s individual-market formulary. ARHOME members should contact their QHP member services directly.

The pending Pathway to Prosperity Section 1115 amendment (submitted January 28, 2025, seeking work requirements for ARHOME members) does not directly change GLP-1 coverage but could reduce the population for which QHP-formulary GLP-1 coverage is available if approved. Status as of 2026-05-10: pending CMS approval.

State PDL + DUR Board Authority (FFS Track)

The GLP-1 agonist PDL hierarchy was updated by AR DMS via a standalone letter dated April 21, 2025 (signed by Cynthia Neuhofel, Pharm.D., DMS Assistant Director/Pharmacy Director; effective June 1, 2025; ARSMT-CD-083567-25):

“Effective June 1, 2025, the GLP-1 agonist PDL class listed below will have noted updates to preferred options for Arkansas Medicaid beneficiaries.

Preferred Agents: Byetta pen (exenatide) — until no more product on the market; Trulicity pen (dulaglutide); Victoza pen (liraglutide).

Point-of-Sale (POS) Approval Criteria: Billed diagnosis of type 2 diabetes mellitus AND [metformin claim in last 90 days OR billed diagnosis of ASCVD]; OR Medicaid pharmacy profile indicates a paid claim in the last 60 days for a GLP-1 receptor agonist.

Non-Preferred Agents: Exenatide, Liraglutide (generic), Mounjaro, Ozempic, Rybelsus, Soliqua, Xultophy.

For any questions, contact the Prime Therapeutics Help Desk at 800-424-7895.”

Critically, Wegovy and Saxenda do not appear on this PDL update — they are handled via standalone DUR-Board PA documents (below). Wegovy and Zepbound are effectively “Non-Preferred PA-required” drugs. The POS criteria require a T2DM diagnosis or prior GLP-1 claim history — there is no POS pathway for chronic weight management at any BMI.

The DUR Board’s authority is confirmed at Pharmacy Provider Manual § 240.000 (Prior Authorization, effective 8-1-21):

“In addition, clinical edits will be established through a system modification enhancement, as well as limits placed on drugs based on age, gender, quantity and dosage, as approved by our Drug Utilization Review Board. Lists of all drugs subject to clinical editing and the criteria for reimbursement are maintained by DHS or its contracted Pharmacy Vendor.”

Wegovy CV (July 17, 2024) — 3 Months Earlier Than Oklahoma

The AR DUR Board approved Wegovy cardiovascular risk-reduction criteria on July 17, 2024, memorialized in the August 14, 2024 DUR Board Provider Memorandum (humanservices.arkansas.gov/wp-content/uploads/PharmMemo8-14-24.pdf). This makes Arkansas one of the earliest non-expansion-of-coverage states to adopt the Wegovy MACE carve-out — approximately three months before Oklahoma (October 9, 2024).

The criteria header states verbatim:

“NOTE: Arkansas Medicaid does not currently cover medications solely for the use of weight loss. PA requests for this medication must demonstrate that the patient has established cardiovascular disease and at risk for a major cardiovascular event.”

Initial approval requires all of the following:

• Established CVD with at least ONE of: history of MI or stent placement or bypass surgery; history of stroke; symptomatic peripheral arterial disease (intermittent claudication with ABI ≤ 0.9, or peripheral arterial revascularization or amputation due to atherosclerotic disease)
• BMI ≥ 27 kg/m²
• At risk for major cardiovascular events (CV death, non-fatal MI, or non-fatal stroke)
• Outlined treatment plan including reduced calorie diet and increased physical activity
• Non-smoker or enrolled in a smoking cessation program (denial criterion: “Current smoker without a cessation plan”)

Denial criteria include: no documented MACE risk; BMI < 27; personal/family history of MTC; MEN2; requested for weight loss only; current smoker without cessation plan.

Required documentation: current chart notes; current labs including HbA1c and lipid panel; current and previous CV therapy; baseline BMI/weight/waist circumference/BP/HR; treatment plan with diet and physical activity plan; lifestyle counseling attestation.

Renewal: 75% utilization compliance; improvement in cardiometabolic parameters and body measurements; continuation of lifestyle modifications; updated chart notes/labs.

Quantity limit: Max of 4 syringes per 28 days (PA required for each strength).

Note: unlike Oklahoma’s October 2024 Wegovy CV criteria, AR’s criteria do not explicitly require HbA1c < 6.5% or a 2-year no-antidiabetic lookback as a denial criterion. AR requires labs including HbA1c but does not codify a diabetes-exclusion threshold — though a T2DM patient would typically be directed to a diabetes-indicated GLP-1 (Mounjaro, Ozempic, Trulicity) instead.

Zepbound OSA (April 16, 2025) — Active-Suicidality Exclusion

The AR DUR Board approved Zepbound OSA-indication-only criteria on April 16, 2025, memorialized in the May 14, 2025 DUR Board Provider Memorandum (humanservices.arkansas.gov/wp-content/uploads/PharmMemo-5-14-25.pdf). Only the 10 mg and 15 mg strengths are covered (maintenance doses); this is the second of the three standalone AR PA documents.

The criteria header states verbatim:

“Arkansas Medicaid does not cover medications solely for weight loss. The criteria listed below pertain to the obstructive sleep apnea indication only.”

Initial approval requires all of the following:

• Moderate-to-severe OSA: AHI ≥ 15 respiratory events per hour confirmed by polysomnography (PSG)
• BMI ≥ 30 kg/m² AND at least ONE weight-related comorbidity: cardiovascular disease, type II diabetes mellitus, dyslipidemia, or hypertension
• Prescribed by or in consultation with a neurologist, pulmonologist, otolaryngologist, or sleep medicine specialist (specialist must have performed the sleep study and provided a report)
• At least 6 months participating in a comprehensive weight management program with documented counseling on behavioral modification, reduced-calorie diet, and increased physical activity
• At least 6-month history of compliant CPAP or BiPAP use without AHI reduction below 15 events per hour

Denial criteria include (verbatim):

• Has not been on a weight management program for at least 6 months
• Has not been compliant with nightly CPAP use
• Prescribed another tirzepatide-containing product or any GLP-1 receptor agonist concurrently
• Personal or family history of MTC; diagnosed with MEN2
• Requested for weight loss only
• Severe gastrointestinal disease including gastroparesis
• History of pancreatitis
• Has a history of suicidal attempts or active suicidal ideation

The suicidal ideation denial criterion is structurally distinctive — most other states’ Zepbound OSA criteria do not include this provision. AR DMS adopted a conservative posture reflecting evolving FDA commentary on GLP-1 and mental health signals; the FDA’s 2024 review found no clear causal evidence of the GLP-1/suicidality link, but AR incorporated the precautionary criterion.

Required documentation: current chart notes; most recent PSG results including post-CPAP/BiPAP AHI; patient-specific OSA symptoms (daytime sleepiness, snoring, AHI events); CPAP/BiPAP usage report; current weight and BMI.

Renewal requires: 75% Zepbound utilization compliance AND compliant CPAP/BiPAP use; positive response in OSA self-reported symptoms vs baseline (reduction in daytime sleepiness, snoring, or AHI); weight/BMI decrease; continuation of comprehensive weight management program.

Quantity limit: 4 injections per 28 days. Initial PA: 6 months.

Wegovy MASH (October 15, 2025)

The AR DUR Board approved Wegovy MASH criteria on October 15, 2025, memorialized in the November 12, 2025 DUR Board Provider Memorandum (humanservices.arkansas.gov/wp-content/uploads/PharmMemo11-12-25.pdf). This is the third and most recently adopted standalone PA document, predating Oklahoma’s MASH criteria by approximately four months.

Initial approval requires all of the following:

• Noncirrhotic MASH with moderate-to-advanced liver fibrosis (F2–F3)
• Fibrosis staging via: liver biopsy results; OR fibrosis score from TWO modalities — at least ONE blood-based NIT (FIB-4, APRI, NFS, ELF or simplified ELF, FibroSure) AND at least ONE imaging test (FibroScan VCTE, 2D shear-wave elastography, point shear-wave elastography, or MRE)
• Prescribed by or in consultation with an endocrinologist, gastroenterologist, or hepatologist
• BMI ≥ 27 kg/m²
• Standard-of-care treatment for cardiometabolic comorbidities and healthy lifestyle counseling
• Alternative causes of fibrosis (alcohol, hepatitis C) ruled out
• No personal or family history of MTC; no MEN2
• T2DM coordination rule: “Beneficiary with Type 2 diabetes mellitus and MASH must utilize a GLP-1 agonist indicated for diabetes” (i.e., Trulicity, Ozempic, or Mounjaro — not Wegovy)

The denial sentence for MASH uses slightly different phrasing than the CV and OSA criteria: “Prior authorization request should not be for weight loss only.”

Required documentation: current chart notes; HbA1c and lipid panel; fibrosis staging documentation (NAS score if biopsy); current and previous MASH therapy; baseline BMI/weight; alcohol intake documentation; treatment plan with diet/physical activity attestation.

Renewal requires: 75% utilization compliance; positive response — either reduction in steatohepatitis without worsening fibrosis OR at least one stage improvement in liver fibrosis without worsening steatohepatitis; continuation of diet and exercise plan.

Quantity limit: 4 injections per month per strength. Initial PA: 6 months; renewal PA: up to 12 months.

The dual-modality fibrosis confirmation option (biopsy OR NIT+imaging combination) is operationally flexible, making the MASH criteria the most diagnostically accessible of the three AR carve-outs for providers with FibroScan capability.

Three-Separate-PA-Documents Architecture vs Iowa’s Unified Pathway

Iowa (Pattern #32) uses a single unified PA form (470-0058, “Incretin Mimetics for Non-Diabetes Indications”) that covers all three indications — MACE, OSA, and MASH — in one submission with one fax number (1-800-574-2515). Arkansas uses three completely separate DUR-Board-approved standalone PA Criteria documents with no consolidated form.

For AR prescribers, the fragmented architecture means selecting the correct PA document for the patient’s indication before submission. All three route through Prime Therapeutics (fax 1-800-424-7976 or CoverMyMeds ePA) but the clinical question sets are different.

PBM: Prime Therapeutics State Government Solutions

Prime Therapeutics State Government Solutions (successor to Magellan Rx following the Centene acquisition and divestiture) is the PBM for AR Medicaid FFS, ARKids, and PASSE-aligned pharmacy claims. The August 2024 DUR Board memo still referenced “Prime Therapeutics/Magellan Rx” jointly; by February 2025 the transition to “Prime Therapeutics State Government Solutions” was complete across all provider communications.

Operational contact information (consistent across all 2024–2026 DUR Board memos):

• Help Desk: 1-800-424-7895 (Monday–Friday, 8:00 a.m.–5:00 p.m. CT, excluding state holidays)
• Clinical PA Fax: 1-800-424-7976 (24 hours/day, 7 days/week)
• Portal: ar.primetherapeutics.com

CoverMyMeds ePA (electronic prior authorization) launched August 1, 2025. The November 12, 2025 DUR Board memo states verbatim:

“Beginning 8/1/2025, the Arkansas Medicaid Prescription Drug Program added a new functionality that accepts electronic prior authorization (ePA) requests via CoverMyMeds, in addition to fax requests. The CoverMyMeds tool simplifies the prior authorization process by prompting prescribers to answer required clinical questions and can offer real-time approval if clinical criteria are met.”

CoverMyMeds Help Desk: 1-866-452-5017. Providers should prefer CoverMyMeds over fax for real-time adjudication on the three Wegovy/Zepbound carve-out PA pathways when documentation is complete at submission.

Effective January 1, 2026, Physician-Administered Drug (PAD) PA processing consolidated under Prime Therapeutics (replacing AFMC). This applies to medical-benefit drugs, not outpatient pharmacy-benefit GLP-1 prescriptions, but prescribers managing both pharmacy and physician-administered drugs for AR Medicaid patients now submit all PAs through one vendor.

2025 Legislative Ratification: HB 1332 Died, ACT 628 Enacted

The 95th Arkansas General Assembly (Regular Session, 2025) was the most directly engaged AR legislative session on GLP-1 coverage in the 34-state series. Two bills with opposite trajectories defined the outcome.

HB 1332 (Pilkington) — GLP-1 Mandate, FAILED

HB 1332 (sponsored by Rep. Aaron Pilkington, R-Knoxville) was titled: “AN ACT TO REQUIRE THE ARKANSAS MEDICAID PROGRAM TO COVER GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS, ALSO KNOWN AS GLP-1 AGONISTS, WHEN PRESCRIBED FOR WEIGHT LOSS; AND FOR OTHER PURPOSES.”

The bill would have added Arkansas Code § 20-77-154 mandating (verbatim from the engrossed March 31, 2025 text):

“No later than the date of issuance of a final federal rule resulting from the proposed federal rule published as Medicare and Medicaid Programs: Contract Year 2026 Policy and Technical Changes … 89 Fed. Reg. 90,340 (December 10, 2024), the Arkansas Medicaid Program shall cover glucagon-like peptide-1 receptor agonists, also known as GLP-1 agonists, when prescribed for weight loss.”

The trigger structure was designed to align AR Medicaid coverage with the Biden-era proposed CMS Contract Year 2026 rule requiring Medicare Part D coverage of anti-obesity medications. HB 1332 passed the House, was engrossed March 31, 2025, and died in Senate committee on May 5, 2025. The proposed federal rule has not been finalized as of 2026-05-10 (the Trump administration has proposed a voluntary payment model instead), meaning even if HB 1332 had passed, the trigger would not have activated.

HB 1424 / ACT 628 — Bariatric Mandate WITH Explicit GLP-1 Exclusion, ENACTED

HB 1424 (sponsored by Rep. Lee Johnson and Sen. Ben Johnson), enacted as Act 628 of the Regular Session, effective January 1, 2026, is titled: “AN ACT TO MANDATE COVERAGE FOR SEVERE OBESITY TREATMENTS; AND FOR OTHER PURPOSES.”

ACT 628 added Arkansas Code § 20-77-154 (the same section number HB 1332 would have used):

“(a) The Arkansas Medicaid Program shall reimburse for the treatment of diseases and conditions caused by severe obesity.

(b) The coverage under subsection (a) of this section shall include coverage for: (1) Bariatric surgery, as recognized by the American Society for Metabolic and Bariatric Surgery; (2) Preoperative care for bariatric surgery; and (3) Post-operative care for bariatric surgery.

(c) This section does not require the Arkansas Medicaid Program to provide coverage for injectable drugs to lower glucose levels or any other drugs prescribed for weight loss.

(d) The Department of Human Services shall apply for any federal waiver, Medicaid state plan amendments, or other authority necessary to implement this section.”

ACT 628 also added Title 23 Subchapter 29 mandating the same bariatric surgery coverage for commercial health benefit plans in Arkansas. “Severe obesity” is defined at § 23-79-2901(6) as BMI ≥ 40 kg/m² OR BMI ≥ 35 kg/m² with an associated comorbidity (hypertension, cardiopulmonary conditions, sleep apnea, or diabetes). Saline Memorial Hospital’s December 31, 2025 release confirmed verbatim: “Act 628 does not cover injectable weight-loss drugs such as Ozempic; it only covers weight-loss surgery and the care associated with it.”

Two structural points distinguish ACT 628’s § 20-77-154(c):

1. “Injectable drugs to lower glucose levels”explicitly covers the GLP-1 class regardless of approved indication — meaning the exclusion is not limited to obesity-labeled GLP-1s.
2. “Any other drugs prescribed for weight loss”encompasses Qsymia, Contrave, phentermine, orlistat, Imcivree, Foundayo, and any future anti-obesity drug class.

Together, HB 1332’s death and ACT 628’s enactment constitute the cleanest affirmative 2025 legislative ratification of a GLP-1 exclusion in the 34-state series. The AR Legislature explicitly chose surgical obesity treatment over pharmaceutical treatment as a policy matter. Arkansas is therefore not a state with “pending” or “under-review” GLP-1 coverage expansion — the 2025 session settled this question for at least the 2026 biennium.

Strange Asymmetry: Androgens for Weight Gain Covered, Anti-Obesity for Weight Loss Excluded

The AR Medicaid State Plan, Attachment 3.1-A Page 5a, Section 12(a)(3) (as approved through SPA 21-0009, effective January 1, 2022) carves IN specific subsets of the federally-excludable drug classes. The verbatim State Plan text:

“The following excluded drugs, set forth on the Arkansas Medicaid Pharmacy Vendor’s Website, are covered:

a. select agents when used for weight gain: Androgenic Agents …”

The structural logic: the State Plan affirmatively carves IN androgenic agents (testosterone replacement products for male hypogonadism, etc.) within the federally-excludable “weight gain” drug class. No analogous carve-in exists for anti-obesity (weight-loss) drugs. The AR Pharmacy Provider Manual § 212.000 Exclusions (effective 8-1-21) echoes this at the administrative level: “Select agents when used for weight gain” is listed as a covered carve-out, while “agents when used for weight loss” receives no coverage designation.

AR DMS therefore has the regulatory mechanism to carve in anti-obesity drugs at the State Plan level — it has done exactly that for androgens. It has affirmatively chosen not to exercise that mechanism for chronic-weight-management GLP-1s.

Arkansas ~37.4% Adult Obesity vs 2025 Legislative Ratification

Per CDC BRFSS 2024 data, Arkansas’s adult obesity prevalence is approximately 37.4%, placing Arkansas among the highest-obesity states in the country. This context makes the regulatory posture politically significant: the state with one of the nation’s highest obesity rates has affirmatively chosen, via both regulatory framework and 2025 legislative action, to exclude GLP-1 receptor agonists for chronic weight management from Medicaid coverage.

The 2025 legislative outcome — ACT 628 mandating bariatric surgery coverage (BMI ≥ 40 or ≥ 35 + comorbidity) while explicitly excluding GLP-1 drugs — reflects a state-level policy preference for surgical over pharmaceutical obesity treatment. Bariatric surgery is the highest-intensity, lowest-volume treatment; GLP-1s are lower-intensity, higher-volume, and substantially higher cost at scale. ACT 628 also extended the bariatric surgery mandate to commercial health benefit plans (Title 23 Subchapter 29), making AR one of the few states to simultaneously mandate surgical obesity coverage in both Medicaid and commercial markets while explicitly excluding drug coverage in both markets.

Appeals: AR DHS Office of Appeals and Hearings

Pharmacy PA denial appeals for FFS and PASSE members route through the AR DHS Office of Appeals and Hearings. Submit a written appeal request within 30 days of the denial date:

• Mailing address: Department of Human Services, Office of Appeals and Hearings, P.O. Box 1437, Slot S101, Little Rock, AR 72203-1437
• Hearings are by telephone unless either party requests in-person
• Final agency decision is binding subject to further appeal to Arkansas state courts

For PASSE members: begin with a PASSE-level grievance/appeal (per your PASSE entity’s State Fair Hearings page), then escalate to DHS Office of Appeals and Hearings.

For ARHOME members: appeal through your QHP’s grievance process first, then escalate to the AR Insurance Department or DHS Office of Appeals and Hearings depending on the denial type.

A chronic-weight-management-only denial will be upheld on appeal given the four-layer authority architecture plus ACT 628. Appeals most likely to succeed:

• Wegovy CV: patient has documented established CVD (MI/stent/bypass/stroke/symptomatic PAD), BMI ≥ 27, non-smoker or cessation program, but PA was denied due to documentation deficiency
• Zepbound OSA: patient has polysomnography confirming AHI ≥ 15, 6-month CPAP/BiPAP failure documented, 6-month weight-management program documented, specialist consultation on file, but PA was denied due to documentation deficiency
• Wegovy MASH: F2/F3 fibrosis confirmed via biopsy or dual-modality NIT+imaging, specialist Rx, BMI ≥ 27, but PA was denied for documentation gap

See the GLP-1 insurance appeal playbook for documentation templates applicable to the AR appeal process.

How AR Compares: OK, IA, AL, KY, LA — Pattern #34

Arkansas is structurally positioned as the only state in the 34-state taxonomy that enacted an affirmative obesity-treatment mandate (bariatric surgery via ACT 628) while simultaneously and explicitly preserving the GLP-1 exclusion at the statutory level. Compare Kentucky (Pattern #21), where legislative action went the other direction — the 2026 SB 65 override nullified Governor Beshear’s positive-coverage amendment.

What Patients Can Do in 2026

Step 1: Identify your program track before anything else.

• FFS or PASSE member? Look at your Medicaid ID card. If it says Prime Therapeutics, Empower, Summit Community Care, or CareSource PASSE — you are on the state PDL track. No chronic-weight-management coverage exists. The three carve-outs (Wegovy CV/MASH, Zepbound OSA) may apply if your physician documents the qualifying indication.
• ARHOME member? Your card will show your QHP carrier (Health Advantage, Ambetter, etc.). Contact your QHP member services to ask whether your specific plan covers Wegovy or Zepbound under the Metallic Drug List. Some individual-market QHPs may cover these drugs for obesity; coverage varies by carrier and plan year.

Step 2: If you have a qualifying non-weight-loss indication, ask your prescriber to pursue the correct PA pathway:

• Established CVD (MI/stent/stroke/symptomatic PAD) + BMI ≥ 27 → Wegovy CV PA
• Moderate-to-severe OSA (AHI ≥ 15 on PSG) + BMI ≥ 30 + CPAP failure → Zepbound OSA PA (after 6 months of CPAP use and 6 months of weight management program)
• F2/F3 noncirrhotic MASH confirmed by liver biopsy or NIT+imaging combination + BMI ≥ 27 → Wegovy MASH PA (endocrinologist/gastroenterologist/hepatologist consult required)

Step 3: If denied, appeal within 30 days. Appeals succeed most often when the indication is valid but documentation was incomplete at initial submission. Gather PSG reports, cardiology notes, liver fibrosis test results, and specialist consultations before appealing.

Step 4: Consider manufacturer patient assistance programs. Novo Nordisk’s NovoCare program and Eli Lilly’s LillyPAP program offer income-based assistance for uninsured or Medicaid-excluded patients. Income thresholds and enrollment requirements change; contact NovoCare (1-844-668-6463) and LillyPAP (1-800-545-5979) directly.

Step 5: Watch the July 2026 DUR Board meeting. The DUR Board meets quarterly in January, April, July, and October. The July 2026 meeting is the next scheduled opportunity for AR DMS to adopt new PA criteria or modify existing ones. The ARHOME Pathway to Prosperity work-requirement amendment (pending CMS approval) is a separate track to monitor.

Sources

1. AR Medicaid DUR Board Memorandum, August 14, 2024 (Wegovy CV-only PA Criteria, effective July 17, 2024) — humanservices.arkansas.gov/wp-content/uploads/PharmMemo8-14-24.pdf
2. AR Medicaid DUR Board Memorandum, May 14, 2025 (Zepbound OSA-only PA Criteria, effective April 16, 2025) — humanservices.arkansas.gov/wp-content/uploads/PharmMemo-5-14-25.pdf
3. AR Medicaid DUR Board Memorandum, November 12, 2025 (Wegovy MASH PA Criteria, effective October 15, 2025; CoverMyMeds ePA launch announcement) — humanservices.arkansas.gov/wp-content/uploads/PharmMemo11-12-25.pdf
4. AR DMS Medicaid Pharmacy Program PDL Update Letter, April 21, 2025 (effective June 1, 2025; signed Cynthia Neuhofel, Pharm.D.; ARSMT-CD-083567-25) — files.providernews.summitcommunitycare.com/ 6360/ARSMT-CD-083567-25--DHS-DMS-Provider-letter-on-GLP-1-Agonists-4.21.25_FINAL-DISTRO.pdf
5. AR Medicaid State Plan Attachment 3.1-A Page 5a, Section 12(a)(3), SPA 21-0009 (effective January 1, 2022; CMS approval December 20, 2021) — medicaid.gov/medicaid/spa/downloads/AR-21-0009.pdf
6. AR Medicaid Pharmacy Provider Manual § 212.000 Exclusions (PHARMACY-1-20, effective 8-1-21) — humanservices.arkansas.gov/wp-content/uploads/ PHARMACY-1-20up.doc
7. 42 U.S.C. § 1396r-8(d)(2) (Federal optional exclusion authority, “Agents when used for anorexia, weight loss, or weight gain”) — law.cornell.edu/uscode/text/42/1396r-8
8. Arkansas Code § 20-77-154 (Treatment of severe obesity) and § 20-77-406 (Prescription limits), as enacted by ACT 628 (HB 1424, 95th General Assembly, Regular Session 2025, effective January 1, 2026)
9. Arkansas HB 1332 (Pilkington; engrossed March 31, 2025; died Senate committee May 5, 2025) — arkleg.state.ar.us
10. ARHOME Section 1115(a) Demonstration (approved December 20, 2021; current approval through December 31, 2026) — medicaid.gov/medicaid/section-1115-demo/demonstration-and-waiver-list/126401
11. CareSource PASSE Pharmacy page verbatim PDL-alignment statement — caresource.com/ar/providers/education/patient-care/pharmacy/caresource-passe/
12. Arkansas Total Care Provider News article (May 16, 2023) listing Saxenda and Wegovy for obesity as “Non-covered benefit”
13. AR DMS February 12, 2025 DUR Board Memorandum (GLP-1 PDL update delay notice; Prime Therapeutics transition)
14. Saline Memorial Hospital release (December 31, 2025): “Act 628 does not cover injectable weight-loss drugs such as Ozempic; it only covers weight-loss surgery and the care associated with it.”
15. CDC BRFSS 2024 data: Arkansas adult obesity prevalence ~37.4%

Frequently Asked Questions

Does Arkansas Medicaid cover Wegovy or Zepbound for weight loss?

No. The DUR Board recurring sentence governs: “Arkansas Medicaid does not currently cover medications solely for the use of weight loss.” Exclusion is anchored at four independent authority levels plus ACT 628 § 20-77-154(c) (effective January 1, 2026). Three FDA-label-restricted carve-outs exist (Wegovy CV/MASH, Zepbound OSA) — none covers chronic weight management.

I am in ARHOME. Where do I check my Wegovy/Zepbound coverage?

Contact your QHP carrier’s member services line directly (Health Advantage/BCBS or Ambetter/Centene). Your coverage is governed by your QHP’s Metallic Drug List, not the AR state PDL or DUR Board PA criteria. The Prime Therapeutics Help Desk (1-800-424-7895) handles FFS and PASSE members only.

What is the phone number and fax for Arkansas Medicaid pharmacy PA?

Prime Therapeutics Help Desk: 1-800-424-7895(Monday–Friday 8am–5pm CT). PA fax: 1-800-424-7976(24/7). Electronic PA via CoverMyMeds (effective August 1, 2025): CoverMyMeds Help Desk 1-866-452-5017. Portal: ar.primetherapeutics.com.

Does Saxenda (liraglutide for obesity) have any coverage pathway?

No. Arkansas Total Care’s May 16, 2023 provider news article explicitly lists Saxenda as a “Non-covered benefit” under AR Medicaid managed care. No DUR-Board-approved PA pathway exists for Saxenda for any indication. The categorical exclusion applies.

Does ACT 628 bariatric surgery coverage already apply?

Yes — ACT 628 is effective January 1, 2026. The AR Medicaid Program is required to cover bariatric surgery (biliopancreatic bypass, laparoscopic adjustable gastric banding, Roux-en-Y, sleeve gastrectomy), preoperative care, and postoperative care for BMI ≥ 40 or BMI ≥ 35 with a comorbidity. DHS must apply for any necessary federal waivers or SPAs to operationalize this mandate (§ 20-77-154(d)).

When is the next Arkansas DUR Board meeting?

The DUR Board meets quarterly: January, April, July, October. The next scheduled meeting after the date of this article is July 2026. Monitor humanservices.arkansas.gov for DUR Board meeting notices and any provider memoranda issued after each meeting.

Why does the Zepbound OSA criteria exclude patients with suicidal ideation?

The April 2025 Zepbound OSA criteria list “history of suicidal attempts or active suicidal ideation” as a denial criterion — one of the most operationally distinctive denial criteria in the 34-state series. This reflects AR DMS’s precautionary posture incorporating evolving FDA commentary on GLP-1 and mental health signals. The FDA’s 2024 review found no clear causal evidence of a GLP-1/suicidality link, but AR adopted the conservative criterion.

Is Arkansas likely to expand GLP-1 coverage in the near future?

Not on the current trajectory. The 2025 legislative session settled the question: HB 1332 (coverage mandate) died in Senate committee; ACT 628 enacted a bariatric surgery mandate with explicit GLP-1 exclusion. The DUR Board does meet quarterly and can add PA criteria at any time, but the legislative exclusion in ACT 628 § 20-77-154(c) represents an affirmative policy choice by the AR Legislature that would require a statutory amendment to reverse.